Clinical trials: Non-hodgkin Lymphoma,B Cell
Non Hodgkin Lymphoma
Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma
Part 1: To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with R/R FL. Part 2: To characterize the activity of acalabrutinib alone or in combination with rituximab in subjects…
- Trial name
- NCT02180711
- Testing
- acalabrutinib, rituximab (IV), Lenalidomide
- Where
- 29 sites in United States, Canada and 1 more
- Volunteers
- 113 people
- Sponsor
- Acerta Pharma BV
Diffuse Large B Cell Lymphoma
Imaging Apoptosis for Lymphoma Treatment Response
Apoptosis is a specific form of cell death that leads to clearance of dead cells without causing inflammation or injury to normal adjacent tissues.
- Trial name
- NCT05048732
- Testing
- 18F-FluorApoTrace
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
This phase II trial is studying how well umbilical cord blood transplant from a donor works in treating patients with hematological cancer.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Chronic Myelogenous Leukemia
- Trial name
- NCT00723099
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine
- Where
- 6 sites in United States
- Volunteers
- 73 people
- Sponsor
- Fred Hutchinson Cancer Center
Lymphoma
Ifosfamide, Teniposide, and Paclitaxel in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00004916
- Testing
- ifosfamide, paclitaxel, teniposide
- Where
- United States
- Sponsor
- Northwestern University
B-cell Acute Lymphoblastic Leukemia
Dual-Targeted Umbilical Cord Blood CAR-T Cells Against CD19 and CD22 for the Treatment of Relapsed or Refractory Acute B-Cell Lymphoblastic Leukemia
This investigator-initiated, prospective, single-arm, phase I dose-escalation trial aims to evaluate the safety and tolerability of anti-CD19/CD22 dual-target cord blood-derived CAR-T cells in adult patients with…
- Trial name
- NCT07838714
- Testing
- Anti-CD19/CD22 Dual-Target Cord Blood CAR-T Cells, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Ruijin Hospital
Lymphoma, Large B-cell, Diffuse
Rituximab Augmentation Following R-CHOP Induction Chemotherapy in Extremely Elderly Patients With Diffuse Large B Cell Lymphoma
Rituximab (R) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) combination is considered as the new gold standard for the first-line treatment of elderly patients with diffuse large B-cell lymphoma…
- Trial name
- NCT01181999
- Testing
- rituximab
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Chonnam National University Hospital
Diffuse Large B Cell Lymphoma (DLBCL)
Dynamic CtDNA-guided Targeted Therapy in DLBCL
This is a prospective, single-arm, noninferiority trial involving patients with previously untreated CD20-positive DLBCL. The aim of this study is to determine the efficacy and safety of treatment stratified based on ctDNA…
- Trial name
- NCT06748521
- Testing
- R-CHOP + X
- Volunteers
- 108 people
- Sponsor
- Ruijin Hospital
Blood And Marrow Transplantation, Leukemia
Infusion of Allogeneic, 3rd Party CD19-specific T Cells
The goal of this clinical research study is to learn if researchers can successfully and safely give patients who have had a stem cell transplant an infusion of white blood cells (called T-cells) that have been collected from an…
- Conditions
- Blood And Marrow Transplantation, Leukemia, Lymphoma
- Trial name
- NCT02274506
- Testing
- Cyclophosphamide, Fludarabine, T-Cell Infusion
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Lymphoma
UCN-01 and Fludarabine in Treating Patients With Recurrent or Refractory Lymphoma or Leukemia
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining UCN-01 with chemotherapy may kill more tumor cells.
- Trial name
- NCT00019838
- Testing
- 7-hydroxystaurosporine, fludarabine phosphate
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Diffuse Large B Cell Lymphoma
Biomarker Guided Treatment in DLBCL
This study is to investigate the strategy of biomarker guided treatment in diffuse large B cell lymphoma
- Trial name
- NCT04025593
- Testing
- Cyclophosphamide, Rituximab, Doxorubicin
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Ruijin Hospital
B-cell Acute Lymphoblastic Leukemia
A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
The researchers are doing this study to find out whether PK-targeted fludarabine is an effective Lymphodepletion (LD) chemotherapy approach for people with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) who will…
- Trial name
- NCT07223021
- Testing
- Fludarabine, Cyclophosphamide, CAR-T
- Where
- 8 sites in United States, Germany and 1 more
- Volunteers
- 130 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lymphoma, B-Cell, Relapse/Recurrence
Dual Target CAR-T Cells in B-cell Lymphoma
Prospectively evaluate the safety and effectiveness of CD19/CD20 dual-target CAR-T cells in the treatment of relapsed/refractory B-cell lymphoma .
- Conditions
- Lymphoma, B-Cell, Relapse/Recurrence, Refractory Lymphoma, Dual-target CAR-T Cells
- Trial name
- CAR-T (NCT04723914)
- Testing
- dual target CAR-T cell therapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- YuLi
Blastoid Variant Mantle Cell Lymphoma, Recurrent Chronic Lymphocytic Leukemia
Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant
This phase II trial studies how well ibrutinib works in treating patients after a donor stem cell transplant for lymphoma that is not responding to treatment or has come back.
- Conditions
- Blastoid Variant Mantle Cell Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Follicular Lymphoma, Recurrent Hodgkin Lymphoma
- Trial name
- NCT02869633
- Testing
- Ibrutinib, Laboratory Biomarker Analysis
- Where
- 5 sites in United States
- Volunteers
- 23 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Follicular Lymphoma, Small Lymphocytic Lymphoma
Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma
This is a phase 2, open label study to assess umbralisib in combination with ublituximab in participants with treatment naïve Follicular Lymphoma (FL) and Small Lymphocytic Lymphoma (SLL).
- Trial name
- NCT03828448
- Testing
- Ublituximab, Umbralisib
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- TG Therapeutics, Inc.
Non-Hodgkin's Lymphoma
Zevalin Plus BuCyE High-dose Therapy in B-cell Non-Hodgkin's Lymphoma
In order to improve the clinical result of high-dose chemotherapy and autologous stem cell transplantation for B-cell non-Hodgkin's lymphoma, Zevalin will be added to the conditioning regimen.
- Trial name
- NCT00336843
- Testing
- Zevalin-BuCyE
- Where
- South Korea
- Volunteers
- 19 people
- Sponsor
- Asan Medical Center
Hemophagocytic Lymphohistiocytosis, B Cell Lymphoma
Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma
For patients who met the inclusion criteria, treatment regimens were administered: Rituximab 375 mg/m², intravenously, once weekly for 4 weeks. Zanubrutinib 160 mg, orally, twice daily for 4 weeks.
- Trial name
- NCT07270835
- Testing
- Rituximab, Zanubrutinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital of Soochow University
B Cell Lymphoma
a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma
This is a single arm study to evaluate the efficacy and safety of CD19 and CD22 targeted prime CAR-T cells therapy for patients with relapsed/refractory B Cell Lymphoma
- Trial name
- NCT04782193
- Testing
- CD19 and CD22 targeted prime CAR- T cells
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Diffuse Large B-Cell Lymphoma
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.
- Trial name
- NCT06717347
- Testing
- Zilovertamab vedotin, Rituximab, Cyclophosphamide
- Where
- 285 sites in United States, Argentina and 33 more
- Volunteers
- 1,046 people
- Sponsor
- Merck Sharp & Dohme LLC
Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL)
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML
This is a Phase 1, open-label, dose escalation study to determine the safety and preliminary efficacy of voruciclib monotherapy in subjects with relapsed/refractory B cell malignancies or AML after failure of standard therapies…
- Conditions
- Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Small Lymphocytic Lymphoma (SLL)
- Trial name
- NCT03547115
- Testing
- voruciclib monotherapy, voruciclib and venetoclax
- Where
- 12 sites in United States
- Volunteers
- 84 people
- Sponsor
- MEI Pharma, Inc.
Lymphoma
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Previously Untreated Aggressive Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.
- Trial name
- NCT00005964
- Testing
- filgrastim, cyclophosphamide, doxorubicin hydrochloride
- Where
- 47 sites in United States
- Volunteers
- 59 people
- Sponsor
- Alliance for Clinical Trials in Oncology
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.